From cardiometabolic risk to heart failure: The role of biomarkers in cardiovascular-kidney-metabolic (CKM) care

Description

Cardiometabolic diseases, including diabetes, chronic kidney disease (CKD), and heart failure, are increasingly recognized as interconnected components of the cardiovascular–kidney–metabolic (CKM) continuum. Many patients remain asymptomatic despite elevated cardiovascular risk, highlighting the need for improved approaches to early identification and risk stratification. 

This educational webinar will examine the role of biomarkers, including natriuretic peptides and cardiac troponins, in assessing cardiovascular risk across cardiometabolic populations, with a particular focus on patients with diabetes. Faculty will review current evidence, clinical trial data, and evolving guideline perspectives related to biomarker use in patients with diabetes and associated cardiovascular risk. 

Through expert discussion and case-based insights, the session will explore how biomarker results may be interpreted within the broader clinical context. Participants will consider how these insights may support risk assessment and inform follow-up evaluation and patient monitoring, particularly in patients with diabetes and elevated risk for heart failure.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), fellows, residents, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Describe the clinical intersection and burden of cardiometabolic diseases, including diabetes, CKD, and heart failure.
• Explain the biological and clinical role of natriuretic peptides and cardiac troponins in assessing cardiovascular and heart failure risk, with a focus on patients with diabetes. 
• Discuss real-world evidence and guideline perspectives on incorporating biomarker testing into clinical workflows, with an emphasis on risk assessment and follow-up strategies in patients with diabetes.

Faculty

Ambarish Pandey, MD, MS
Associate Professor of Internal Medicine 
Divisions of Cardiology and Geriatrics
Medical Director, HFpEF Program
Texas Health Resources Clinical Scholar
Principal Investigator - CardioMetabolic Research Unit (CMRU)
Associate Program Director for IM Residency Training
UT Southwestern Medical Center
Dallas, Texas

Jennifer Green, MD
Professor of Medicine, Division of Endocrinology
Duke University School of Medicine
Duke Clinical Research Institute
President-Elect, Medicine and Science, American Diabetes Association
Durham, North Carolina

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (ADLM) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Ambarish Pandey, MD, MS
  • Honorarium and/or Expenses: Baylor Scott and White Research Institute, Boehringer Ingelheim, iRhythm Technologies, Tourmaline Bio, Alnylam, Abbott, Anumana, Novartis.
  • Consulting Fees: Tricog Health Inc, Lilly, Rivus, Roche Diagnostics, Axon Therapies, Edward Lifesciences, Science37, Bayer, Medical AI, Abbott, Antlia Biosciences, Sarfez Pharmaceuticals, Ultromics.
  • Grant and/or Research Support: Applied Therapeutics, Roche, Ultromics, Gilead Sciences, Bayer, and AstraZeneca
  • Committee, Board, and/or Advisory Board Membership: Astra Zeneca, Bayer, Alnylam, Kilele Health, Acorai, Merck, Kardigan, Tenax Pharma.
• Jennifer Green, MD
  • Consulting Fees: Aqua, AstraZeneca, Bayer, Boehringer Ingelheim, Fractyl, vTv Medpace, Lilly, Novo Nordisk, Roche, Sparrow, Vertex, Zealand
  • Grant and/or Research Support: Cour, GentiBio, Merck, Boehringer Ingelheim, Metsera
  • Stocks and/or Bonds: BDI Inc.

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity will be submitted for 1.0 ACCENT® continuing education credits

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].